Skip to main content

Table 1 Difference in baseline characteristics between group A and group B

From: SARS-CoV-2 serology increases diagnostic accuracy in CT-suspected, PCR-negative COVID-19 patients during pandemic

Baseline characteristics In total
Absolute value (%)
Group A
(PCR + ; CT ±)
Absolute value (%)
Group B
(PCR-; CT +)
Absolute value (%)
Number of patients 153 (100) 107 (70) 46 (30)
Age (median) 68 67 69
Sex (male/female) 95/58 70/37 25/21
Comorbidities (Comorbidity Score index points*)    
Coronary artery diseasea (1 point) 17 (11) 15 (14) 2 (4)
Heart diseaseb (1 point) 41 (27) 27 (25) 14 (30)
Cerebrovascular diseasec (1 point) 11 (7) 6 (5) 5 (11)
Dementia/Parkinson disease (1 point) 17 (11) 8 (8) 9 (20)
Gastric ulcer disease (1 point) 5 (3) 4 (4) 1 (2)
Chronic pulmonary disease (1 point) 17 (11) 12 (11) 5 (11)
Peripheral vascular disease (1 point) 9 (6) 7 (7) 2 (4)
Mild liver diseased (1 point) 1 (1) 1 (1) 0 (0)
Liver cirrhosis (3 point) 4 (3) 3 (3) 1 (2)
Diabetes without end organ failure (1 point) 22 (14) 18 (17) 4 (9)
Diabetes with end organ failure (2 points) 8 (5) 7 (7) 1 (2)
Renal insufficiency (2 points) 14 (9) 11 (10) 3 (7)
Active tumor diseasee (2 points) 11 (7) 9 (8) 2 (4)
Metastatic tumor disease (6 points) 16 (10) 8 (8) 8 (17)
AIDS (6 points) - - -
Comorbidity Score points in total (median/mean) 314 (1/2.05) 209 (1/1.95) 105 (1/2.28)
Median duration of hospitalization in days 16 16 13.5
Number of patients with typical CT findings compatible with a high level of certainty for COVID-19 125 (82) 85 (79) 30 (65)
Deaths 25 (16) 18 (17) 7 (15)
ICU admission 53 (35) 41 (38) 12 (26)
Treatment (Remdesivir) 17 17 0
  1. *Modified comorbidity index referring to Charlson et al. [11].
  2. aIncluding stenting or aortocoronary bypass;bincluding arterial fibrillation, congestive heart failure; cincluding transient ischemic attack (TIA), stroke; ddefined as severe steatosis hepatis; eincluding solid tumours and haematological malignancies.